{'fraction_non_alphanumeric': 0.03184713375796178, 'fraction_numerical': 0.014012738853503185, 'mean_word_length': 5.288, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long-term albumin administration in decompensated cirrhosis.

Cirrhosis of the liver is one of the common mortality and morbidity cause worldwide. 170,000 individuals die from cirrhosis per year in Europe (1,2). It has a heavy burden on health care costs. Once cirhosis decompensates, such as ascites, gastrointetinal bleeding, hepatorenal syndrome and encephalopathy, prognosis is poor and median survival time is about 2 years (3,4). There is no sole approach to prevent and/or treat all of the complications. Each complications are treated by various therapeutic strategies individually. Actually, we need overall therapeutic approaches to prevent and/or treat all of the complications, thus improving quality of life and survival, reducig hospital admissions and health care costs.